Peptide comparisons

Retatrutide vs tirzepatide compared: receptor targets, trial weight-loss data, regulatory status and how each was given in trials. A plain breakdown of the two.

Tirzepatide vs semaglutide: dual versus single receptor action, what the STEP and SURMOUNT trials reported, approvals and formulations, side by side.

Retatrutide vs semaglutide: triple versus single receptor action, trial weight-loss data, approval status and how each is given, set out side by side.

BPC-157 vs TB-500 compared: mechanisms, the preclinical repair evidence, human-data gaps, and why the two peptides are so often studied together as a stack.

CJC-1295 vs sermorelin compared: half-life, growth hormone and IGF-1 data, regulatory history, and the practical differences between the two GHRH analogues.

Tesamorelin vs CJC-1295 compared: both GHRH analogues, but one completed Phase 3 trials and won FDA approval. Evidence, mechanism and status side by side.

NAD+ vs NMN compared: direct coenzyme versus oral precursor, what human trials actually show, delivery routes and the regulatory picture in the EU and US.

MOTS-c vs NAD+ compared: a mitochondrial signalling peptide against the core energy coenzyme. Mechanisms, evidence stages, and why only one is a peptide.

CJC-1295 vs ipamorelin compared: two receptors, two mechanisms, and why the two are studied together rather than against each other. Plus DAC vs no-DAC.

Melanotan 2 vs melanotan 1 compared: receptor selectivity, delivery format, and the fact that one is an authorised EU medicine and the other is not.

NAD+ and nicotinamide riboside are not alternatives: one is the coenzyme, the other a precursor to it. What that means for route, formulation and evidence.

The same molecule in two products with different evidence. What separates an injectable GHK-Cu pen from a cosmetic copper peptide serum.